Developing A Rapid Transfer from Opioid Full Agonist to Buprenorphine: “Ultrarapid Micro-Dosing” Proof of Concept

References

• Azar, P., J. S. H. Wong, S. Jassemi, E. Moore, D. X. Vo, M. Nikoo, and S. Young. 2020. “A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder.” The American Journal on Addictions. doi:10.1111/ajad.13050.
   Web of Science ®Google Scholar
• Becker, W. C., J. W. Frank, and E. L. Edens. 2020. Switching from high-dose, long-term opioids to buprenorphine: A case series. Annals of Internal Medicine 173 (1):70–71. doi:10.7326/L19-0725.
   PubMed Web of Science ®Google Scholar
• Brar, R., N. Fairbairn, C. Sutherland, and S. Nolan. 2020. Use of a novel prescribing approach for the treatment of opioid use disorder: Buprenorphine/naloxone micro-dosing – a case series. Drug and Alcohol Review 39 (5):588–94. doi:10.1111/dar.13113.
   PubMed Web of Science ®Google Scholar
• British Columbia Centre on Substance Use. 2017. “A guideline for the clinical management of opioid use disorder.” British Columbia Centre on Substance Use. https://www.bccsu.ca/wp-content/uploads/2017/06/BC-OUD-Guidelines_June2017.pdf Acccessed 8 February 2022.
   Google Scholar
• Callan, J., J. Pytell, J. Ross, and D. A. Rastegar. 2020. Transition from methadone to buprenorphine using a short-acting agonist bridge in the inpatient setting: A case study. Journal of Addiction Medicine 14 (5). . doi:10.1097/ADM.0000000000000623.
   PubMed Web of Science ®Google Scholar
• Caulfield, M. D. G., R. Brar, C. Sutherland, and S. Nolan. 2020. Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine/naloxone for the treatment of opioid use disorder using a microdosing approach. BMJ Case Reports 13 (3):e233715. doi:10.1136/bcr-2019-233715.
   PubMedGoogle Scholar
• Choi, M., H. Kim, H. Qian, and A. Palepu. 2011. Readmission rates of patients discharged against medical advice: A matched cohort study. PloS One 6 (9). doi:10.1371/journal.pone.0024459.
   Web of Science ®Google Scholar
• Davis, M. P., G. Pasternak, and B. Behm. 2018. Treating chronic pain: An overview of clinical studies centered on the buprenorphine option. Drugs 78 (12):1211–28. doi:10.1007/s40265-018-0953-z.
   PubMed Web of Science ®Google Scholar
• de Aquino, J. P., C. Fairgrieve, S. Klaire, and G. Garcia-Vassallo. 2020. Rapid transition from methadone to buprenorphine utilizing a micro-dosing protocol in the outpatient veteran affairs setting. Journal of Addiction Medicine 14 (5). . doi:10.1097/ADM.0000000000000618.
   PubMed Web of Science ®Google Scholar
• DeWeese, J. P., J. R. Krenz, S. E. Wakeman, and A. M. Peckham. 2021 May. Rapid buprenorphine microdosing for opioid use disorder in a hospitalized patient receiving very high doses of full agonist opioids for acute pain management: Titration, Implementation barriers, and strategies to overcomes. Substance Abuse 1–6. doi:10.1080/08897077.2021.1915914.
   Web of Science ®Google Scholar
• Ghosh, S. M., S. Klaire, R. Tanguay, M. Manek, and P. Azar. 2019. A review of novel methods to support the transition from methadone and other full agonist opioids to buprenorphine/naloxone sublingual in both community and acute care settings. Canadian Journal of Addiction 10 (4):41–50. doi:10.1097/CXA.0000000000000072.
   Web of Science ®Google Scholar
• Glasgow, J. M., M. Vaughn-Sarrazin, and P. J. Kaboli. 2010. Leaving against medical advice (AMA): Risk of 30-day mortality and hospital readmission. Journal of General Internal Medicine 25 (9):926–29. doi:10.1007/s11606-010-1371-4.
   PubMed Web of Science ®Google Scholar
• Greenwald, M. K., C. Ellyn Johanson, D. E. Moody, J. H. Woods, M. R. Kilbourn, R. A. Koeppe, C. R. Schuster, and J. Kar Zubieta. 2003. Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28 (11):2000–09. doi:10.1038/sj.npp.1300251.
   PubMed Web of Science ®Google Scholar
• Gudin, J., and J. Fudin. 2020. A narrative pharmacological review of buprenorphine: A unique opioid for the treatment of chronic pain. Pain and Therapy 9 (1):41–54. doi:10.1007/s40122-019-00143-6.
   PubMed Web of Science ®Google Scholar
• Hämmig, R., A. Kemter, J. Strasser, U. von Bardeleben, B. Gugger, M. Walter, K. M. Dürsteler, and M. Vogel. 2016. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: The bernese method. Substance Abuse and Rehabilitation 7 (July):99–105. doi:10.2147/SAR.S109919.
   PubMedGoogle Scholar
• Hser, Y.-I., E. Evans, D. Huang, and D. M. Anglin. 2004. Relationship between drug treatment services, retention, and outcomes. Psychiatric Services 55 (7):767–74. doi:10.1176/appi.ps.55.7.767.
   PubMed Web of Science ®Google Scholar
• Hser, Y.-I., L. J. Mooney, A. J. Saxon, K. Miotto, D. S. Bell, Y. Zhu, D. Liang, and D. Huang. 2017a. High mortality among patients with opioid use disorder in a large healthcare system. Journal of Addiction Medicine 11 (4):315. doi:10.1097/ADM.0000000000000312.
   PubMed Web of Science ®Google Scholar
• Indivior UK Limited. 2007. “SUBLOCADE product monograph.” https://pdf.hres.ca/dpd_pm/00041074.PDF Accessed 8 February 2022.
   Google Scholar
• Jafari, S., and R. Rafizadeh. 2021. Successful transition from high-dose methadone to buprenorphine via microdosing in the outpatient setting: A case report. The Canadian Journal of Hospital Pharmacy 74 (1). doi:10.4212/cjhp.v74i1.3046.
   PubMed Web of Science ®Google Scholar
• Kampman, K., and M. Jarvis. 2015. American society of addiction medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. Journal of Addiction Medicine 9 (5):358–67. doi:10.1097/ADM.0000000000000166.
   PubMed Web of Science ®Google Scholar
• Klaire, S., R. Zivanovic, S. Pamela Barbic, R. Sandhu, N. Mathew, and P. Azar. 2019. Rapid micro‐induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series. The American Journal on Addictions 28 (4):262–65. doi:10.1111/ajad.12869.
   PubMed Web of Science ®Google Scholar
• Lee, D. S., J. E. Hann, S. S. Klaire, M. Nikoo, M. D. Negraeff, and P. Rezazadeh-Azar. 2020. Rapid induction of buprenorphine/naloxone for chronic pain using a microdosing regimen. A & A Practice 14 (2):44–47. doi:10.1213/xaa.0000000000001138.
   PubMed Web of Science ®Google Scholar
• Lintzeris, N., L. A. Monds, C. Rivas, S. Leung, A. Dunlop, D. Newcombe, C. Walters, Galea, S., White, N., Montebello, M. et al . 2018. Transferring patients from methadone to buprenorphine: The feasibility and evaluation of practice guidelines. Journal of Addiction Medicine 12 (3):234–40. doi:10.1097/ADM.0000000000000396.
   PubMed Web of Science ®Google Scholar
• Mannelli, P., K. S. Peindl, T. Lee, K. S. Bhatia, and L.-T. Wu. 2012. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: State of the art and new perspectives. Current Drug Abuse Reviews 5 (1):52–63. doi:10.2174/1874473711205010052.
   PubMedGoogle Scholar
• Maremmani, I., and G. Gerra. 2010. Buprenorphine‐based regimens and methadone for the medical management of opioid dependence: Selecting the appropriate drug for treatment. The American Journal on Addictions 19 (6):557–68. doi:10.1111/j.1521-0391.2010.00086.x.
   PubMed Web of Science ®Google Scholar
• Marwah, R., C. Coons, J. Myers, and Z. Dumont. 2020. Buprenorphine-naloxone microdosing. Canadian Family Physician 66 (12):891–894. doi:10.46747/cfp.6612891.
   PubMed Web of Science ®Google Scholar
• Mattick, R. P., R. Ali, J. M. White, S. O’Brien, S. Wolk, and C. Danz. 2003. Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction 98 (4):441–52. doi:10.1046/j.1360-0443.2003.00335.x.
   PubMed Web of Science ®Google Scholar
• Mattick, R. P., C. Breen, J. Kimber, and M. Davoli. 2009. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD002209.pub2.
   PubMed Web of Science ®Google Scholar
• Mattick, R. P., C. Breen, J. Kimber, and M. Davoli. 2014. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews (2). doi:10.1002/14651858.CD002207.pub4.
   PubMed Web of Science ®Google Scholar
• Nielsen, S., L. Briony, L. Degenhardt, L. Gowing, C. Kehler, and N. Lintzeris . 2016. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database of Systematic Reviews 5. doi:10.1002/14651858.CD011117.pub2.
   PubMed Web of Science ®Google Scholar
• Nolan, N. S., L. R. Marks, S. Y. Liang, and M. J. Durkin. 2021. Medications for opioid use disorder associated with less against medical advice discharge among persons who inject drugs hospitalized with an invasive infection. Journal of Addiction Medicine 15 (2):155–58. doi:10.1097/ADM.0000000000000725.
   PubMed Web of Science ®Google Scholar
• Raheemullah, A., and A. Lembke. 2021. Buprenorphine induction without opioid withdrawal: A case series of 15 opioid-dependent inpatients induced on buprenorphine using microdoses of transdermal buprenorphine. American Journal of Therapeutics 28 (4). . doi:10.1097/MJT.0000000000001108.
   Web of Science ®Google Scholar
• Randhawa, P. A., R. Brar, and S. Nolan. 2020. Buprenorphine–naloxone ‘microdosing’: An alternative induction approach for the treatment of opioid use disorder in the wake of north america’s increasingly potent illicit drug market. Canadian Medical Association Journal 192 (3):73. doi:10.1503/cmaj.74018.
   PubMed Web of Science ®Google Scholar
• Rosado, J., S. L. Walsh, G. E. Bigelow, and E. C. Strain. 2007. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug and Alcohol Dependence 90 (2–3):261–69. doi:10.1016/j.drugalcdep.2007.04.006.
   PubMed Web of Science ®Google Scholar
• Rozylo, J., K. Mitchell, S. E. D. Mohammadali Nikoo, S. P. Barbic, D. Lin, S. Mathias, and P. Azar. 2020. Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach. Addiction Science & Clinical Practice 15 (1):1–6. doi:10.1186/s13722-020-0177-x.
   PubMed Web of Science ®Google Scholar
• Sandhu, R., R. Zivanovic, S. Klaire, M. Nikoo, J. Rozylo, and P. Azar. 2019. Buprenorphine/naloxone induction for treatment of acute on chronic pain using a micro-dosing regimen: A Case report. Canadian Journal of Pain 3 (1):79–84. doi:10.1080/24740527.2019.1599279.
   PubMed Web of Science ®Google Scholar
• Stein, M. D., P. Cloe, and P. D. Friedmann. 2005. Brief report: Buprenorphine retention in primary care. Journal of General Internal Medicine 20 (11):1038–41. doi:10.1111/j.1525-1497.2005.0228.x.
   PubMed Web of Science ®Google Scholar
• Ti, L., and L. Ti. 2015. “Leaving the Hospital against Medical Advice among People Who Use Illicit Drugs: A Systematic Review.” American Journal of Public Health 105 (12):e53–59. doi:10.2105/AJPH.2015.302885.
   PubMed Web of Science ®Google Scholar
• Walley, A. Y., J. K. Alperen, D. M. Cheng, M. Botticelli, C. Castro-Donlan, J. H. Samet, and D. P. Alford. 2008. Office-based management of opioid dependence with buprenorphine: Clinical practices and barriers. Journal of General Internal Medicine 23 (9):1393–98. doi:10.1007/s11606-008-0686-x.
   PubMed Web of Science ®Google Scholar
• Wesson, D. R., and W. Ling. 2003. The clinical opiate withdrawal scale (COWS). Journal of Psychoactive Drugs 35 (2):253–59. doi:10.1080/02791072.2003.10400007.
   PubMed Web of Science ®Google Scholar
• White, L. D., A. Hodge, R. Vlok, K. E. Glenn Hurtado, and T. M. Melhuish. 2018. Efficacy and adverse effects of buprenorphine in acute pain management: Systematic review and meta-analysis of randomised controlled trials. British Journal of Anaesthesia 120 (4):668–78. doi:10.1016/j.bja.2017.11.086.
   PubMed Web of Science ®Google Scholar
• Whitley, S. D., N. L. Sohler, H. V. Kunins, A. Giovanniello, L. Xuan, G. Sacajiu, and C. O. Cunningham. 2010. Factors associated with complicated buprenorphine inductions. Journal of Substance Abuse Treatment 39 (1):51–57. doi:10.1016/j.jsat.2010.04.001.
   PubMed Web of Science ®Google Scholar
• Wong, J. S. H., M. Nikoo, J. N. Westenberg, J. G. Suen, J. Y. C. Wong, R. M. Krausz, C. G. Schütz, Vogel, M., Sidhu, J. A., Moe, J. et al. 2021. Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: Protocol for an open-label, parallel-group, superiority, randomized controlled trial. Addiction Science & Clinical Practice 16 (1):11. doi:10.1186/s13722-021-00220-2.
   PubMed Web of Science ®Google Scholar